The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

Researchers have defined a new genetic disease caused by a mutation in the IVNS1ABP gene. The condition marks a rare ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

Scientists have identified a previously unknown genetic disease that causes premature aging and cognitive impairment. The ...

Scientists at Sanford Burnham Prebys Medical Discovery Institute and an international team of collaborators have defined a new genetic disease marked by premature aging and deficits in brain function.

In 2006, Kyoto University’s Professor Yamanaka Shin’ya made a groundbreaking discovery: a method to reprogram ordinary body cells such as skin, nerve, or bone cells into a highly adaptable, ...